Metformin and GLP-1 receptor agonists significantly reduce asthma attacks in patients with type 2 diabetes, offering ...

Stress hormones, not impaired insulin signaling, may underlie obesity-related diabetes, according to Rutgers research.

Study estimates 136.8 million U.S. adults are eligible for semaglutide, a popular therapy for diabetes, weight loss, and cardiovascular disease.

Glucagon-like peptide-1 (GLP-1) agonist are a family of medications that help manage blood sugar in patients with type 2 ...

More than half of all adults in the U.S. are eligible for semaglutide (Ozempic, Wegovy, Rybelsus), researchers estimated.

Novo Nordisk and Eli Lilly are facing scores of personal injury claims for allegedly failing to warn patients about side ...

New research shows that weight loss medications can stop the progression of prediabetes. Experts don’t all agree on such a ...

Biotech companies are racing to find Ozempic 2.0, hoping for a slice of a multi-billion-dollar industry. A few stand-out ...

However, while Wegovy is prescribed by the NHS for weight management, Rybelsus is not licensed for such and is only available as a treatment for Type 2 diabetes. There are other limitations too. In ...

It’s hard to watch the news or scroll through social media without encountering stories about weight loss drugs like ...

The study is the first set of global estimates directly linking diabetes prevalence with treatment coverage over a ...